Clinical application of PIR classification in the evaluation of liver fibrosis regression
10.3969/j.issn.1001-5256.2019.06.039
- VernacularTitle:肝纤维化逆转病理PIR分型临床应用的评价
- Author:
Mengyang ZHANG
1
;
Yameng SUN
;
Xinyan ZHAO
Author Information
1. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
liver cirrhosis;
biopsy, needle;
PIR classification;
review
- From:
Journal of Clinical Hepatology
2019;35(6):1358-1360
- CountryChina
- Language:Chinese
-
Abstract:
Liver biopsy has been regarded as the gold standard for the assessment of liver fibrosis regression. In 2017, Liver Research Center, Beijing Friendship Hospital, proposed a new classification called PIR classification for the evaluation of liver fibrosis regression in patients with chronic hepatitis B after antiviral therapy, which was also called “Beijing classification”. This classification is new breakthrough based on conventional staging and grading systems, quantitative assessment methods for liver fibrosis, and the concept of liver biopsy. This article discusses the prospects and shortcomings of PIR classification.
